ResMed Jumps On Board As Nyxoah Raises €25m For Neurostim Apnea Device
Executive Summary
The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.
You may also be interested in...
Nyxoah Plans $70M+ IPO As It Starts IDE Trial For Neurostim Apnea Device
Belgian firm will float on Euronext Brussels; ResMed and Cochlear among existing investors who will invest in at least 25% of shares.
New-Gen Devices Offer Sleep Apnea Patients Alternative CPAP Routes
With half or more of all diagnosed obstructive sleep apnea patients who need continuous positive airway pressure machines unwilling or unable to use these devices, there’s a large unmet need for an alternative treatment. Startups are rising to the challenge with neuromodulation platforms, a mouthguard-like suction device, a nasal device with microblowers, and a vibrating device that nudges patients to turn on their sides.
Report Digest: Discussing What's Going On With Prostate Cancer Diagnosis And Treatment
In this edition of Report Digest, UK-based reporter Barnaby Pickering talks about the prostate cancer diagnostics and minimally invasive treatments markets with analyst Phil Greenfield. The two discuss ongoing developments in both treatment and diagnosis, while exploring driving and limiting factors for both.